Form 8-K

8-K — ANAVEX LIFE SCIENCES CORP.

Accession: 0001731122-26-001000

Filed: 2026-08-03

Period: 2026-08-03

CIK: 0001314052

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7823_8-k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7823_ex99-1.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7823_8-k.htm · Sequence: 1

false

0001314052

2026-08-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 3, 2026

ANAVEX

LIFE SCIENCES CORP.

(Exact

name of Registrant as Specified in Its Charter)

Nevada

001-37606

98-0608404

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

630

5th Avenue, 20th Floor

New

York, NY USA

10111

(Address of Principal

Executive Offices)

(Zip Code)

Registrant’s

Telephone Number, Including Area Code: 1-844-689-3939

Check the appropriate

box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, par value

$0.001 per share

AVXL

Nasdaq Stock Market LLC

Indicate by check

mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth

company ☐

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 3, 2026, Anavex Life Sciences Corp. (“Anavex” or

the “Company”) issued a press release announcing plans to refresh Anavex’s Board of Directors (the “Board”)

at its 2026 Annual Meeting of Stockholders(the “Press Release”). The Press Release includes an open letter to Anavex’s

stockholders responding to the preliminary proxy statement filed by PVG Asset Management Corporation and Patrick S. Adams, which seeks

to replace the entire Anavex Board.

A copy of the Press Release is furnished as Exhibit 99.1 to this Current

Report and is incorporated herein by reference.

The information included in this Item 7.01, including Exhibit 99.1, shall

not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the

Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated August 3, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.

Date:

August 3, 2026

By:

/s/ Sandra Boenisch

Sandra Boenisch, CPA, CGA

Principal Financial Officer, Treasurer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7823_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Anavex Life Sciences Announces Plans to Refresh

Board to Continue Overseeing Critical Progress

and Stockholder Value Creation

Nominates Two New Independent Directors, Mr. Gautam

Patel and Dr. Adrian Senderowicz,

Who Bring Deep, Relevant Experience in Life Sciences

Mr. Patel and Dr. Senderowicz to Stand for Election

at 2026 Annual Meeting with Independent Directors

Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger and Dr. Claus van der Velden

Urges Stockholders to Reject Attempt by PVG Asset

Management Corporation and Patrick S. Adams to Acquire Control of the Company

Issues Open Letter to Stockholders and Files Preliminary

Proxy Statement

NEW YORK, NY, August 3, 2026 – Anavex Life Sciences Corp. (“Anavex”

or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing

innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that

the Executive Committee of the Company’s Board of Directors (the “Executive Committee”) has taken significant steps

to continue overseeing critical progress to enhance stockholder value.

The Executive Committee announced that it is recommending a refreshed slate

of directors to the Company’s stockholders through the nomination of two new independent candidates, Mr. Gautam Patel and Dr. Adrian

Senderowicz. In identifying these candidates, the Board focused on individuals whose experience aligns with the company’s strategic

priorities. Mr. Patel and Dr. Senderowicz bring significant life sciences industry experience across leadership, strategy and drug development

at the executive and Board levels, as well as expertise in capital markets, clinical development and FDA regulatory matters that the Board

believes will support the Company’s growth and advance programs toward market approval and commercialization.

Mr. Patel and Dr. Senderowicz, along with independent chairperson Dr. Jiong

Ma, and independent directors Dr. Peter Donhauser, Dr. Axel Paeger and Dr. Claus van der Velden, will comprise the six Anavex nominees

standing for reelection at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Dr. Christopher Missling,

former Chief Executive Officer of Anavex, who refused to step down from the Board upon his termination “for cause”, and independent

director Dr. Steffen Thomas, have not been renominated for election and will no longer be members of the Board after the 2026 Annual Meeting.

In connection with the 2026 Annual Meeting, Anavex filed its preliminary

proxy statement with the Securities and Exchange Commission (the “SEC”) on July 31, 2026. As further described in

the preliminary proxy statement, the Anavex Board has established an Executive Committee to exercise the power of the Board in the management

of the business and affairs of the Company. The Executive Committee consists of Dr. Jiong Ma, Dr. Axel Paeger and Dr. Claus van der Velden.

Anavex’s preliminary proxy statement and, after the filing thereof, its definitive proxy statement can be accessed for free by visiting

EDGAR on the SEC website at www.SEC.gov. Once Anavex files its definitive proxy materials with the SEC, they will also be mailed to stockholders

and will include a WHITE proxy card with instructions on how to vote FOR all six Anavex nominees comprising the refreshed

Anavex Board. Your vote FOR all six Anavex nominees comprising the refreshed Anavex Board on the WHITE card will be critical.

The current Anavex Board members standing for reelection at the 2026 Annual

Meeting issued the following open letter to Anavex stockholders:

Dear Valued Anavex Stockholders,

Your current Board members standing for

election at the 2026 Annual Meeting have taken decisive action to stabilize the Company and create value for stockholders, including working

with the management team that is executing a strategy focusing on our lead candidate for patients with Alzheimer’s disease, oral

blarcamesine (ANAVEX®2-73) and identifying and nominating Mr. Patel and Dr. Senderowicz as highly qualified candidates for election

to the Board. The Company continues to have a strong cash runway and no long-term debt, and we are focused on ensuring we maximize our

use of capital and deliver on our goal of enhancing stockholder value.

We are working with urgency while ensuring the Company’s

operations continue without disruption following our termination “for cause” of former CEO Christopher Missling and the resulting

delay in filing Anavex’s quarterly report with the SEC. We appointed Dr. Terrie Kellmeyer, the Company’s former Senior Vice

President of Clinical Development and a Senior Advisor to Anavex, as interim CEO to oversee this period of transition. Dr. Kellmeyer spent

her entire career in drug development building and leading clinical and regulatory functions across the full lifecycle of drug development.

We are confident she is the right person to support the Company at this time.

Your Refreshed Anavex Board

Your current Board members standing for reelection are entirely

independent and will continue to bring critical institutional knowledge that we believe will advance the right path forward. Following

a thorough search process, we are also nominating two new, independent candidates, Mr. Gautam Patel and Dr. Adrian Senderowicz, who will

bring significant, relevant life sciences experience and complementary skills to the Board that are expected to immediately contribute

to the Company’s strategy and help create value across the business. Upon election, half of the Anavex Board will have been refreshed

since February 2026, and all of the Board members will be independent.

The four independent Anavex directors and two independent nominees

standing for election are:

● Dr. Jiong Ma (Independent Chairperson), who has over 30 years of experience investing in, building and scaling technology

and life-sciences companies globally and brings deep financial, transactional and capital markets expertise to the Board. She has substantial

experience investing in, partnering with and working with management teams to set strategy for disruptive technology and life sciences

companies to shape the business, accelerate growth and drive long-term stockholder value.

● Dr. Peter Donhauser, a physician and clinical research leader with more than 20 years of experience in integrated medical care,

clinical trial oversight and private practice leadership, leading research across numerous trials for some of the world’s leading

global pharmaceutical companies. He has practiced osteopathic medicine in private practice since 2000, specializing in an integrated approach

to patient care, providing the Board with valuable clinical and patient-centered expertise.

● Dr. Axel Paeger, an experienced healthcare executive and corporate leader with more than 30 years of clinical, operational

and executive leadership experience. Dr. Paeger currently serves as Chief Executive Officer of AMEOS Group, which he founded as a start-up

in 2002 and scaled into one of Europe’s leading healthcare providers. He is a medically trained executive leader who brings deep

experience in healthcare to the Board.

● Mr. Gautam Patel, an experienced investment executive with over 30 years of corporate finance, investment management and board

leadership experience. Mr. Patel brings extensive capital allocation, investment and financial advisory expertise to the Board, with a

proven track record of executing growth-focused investments and guiding corporate strategy across the life sciences, financial services

and technology sectors.

● Dr. Adrian Senderowicz, an accomplished pharmaceutical executive and physician-scientist with over 30 years of clinical and

regulatory leadership experience across the life sciences industry. Dr. Senderowicz brings deep drug development, clinical research and

global regulatory expertise to the Board, with a proven track record of advancing novel therapeutics through critical international approvals

to drive growth and long-term value.

● Dr. Claus van der Velden, an accomplished finance executive with more than two decades of experience leading finance, governance

and enterprise oversight functions for publicly traded and technology-driven companies in Germany. Since May 2021, he has served as Chief

Financial Officer and Managing Director of NetCologne GmbH, a regional telecommunications provider in Germany.

The Current Anavex Board Members Standing for Reelection are Advancing a Clear Plan to Create Stockholder Value

We have taken steps to address governance at the Board-level

and established interim leadership of the Company. The current Anavex Board members standing for reelection are highly engaged with leadership

and helping oversee continued progress of Anavex’s development pipeline.

The business update we provided on July 30 underscores that we

remain firmly committed to the Company’s lead candidate oral blarcamesine (ANAVEX®2-73) for patients with Alzheimer's disease,

and we are prioritizing engagement with the U.S. FDA to align on a clear, data-driven regulatory and clinical development strategy.

With our support, Anavex is prioritizing programs that the Company

believes have the greatest potential for success. The Company’s strategy concentrates resources on blarcamesine across three CNS

indications: early Alzheimer's disease and Rett syndrome, where the clinical and regulatory foundation is most advanced, and on Fragile

X syndrome, where FDA Orphan Drug Designation, supportive preclinical and biomarker data, and the absence of any approved therapy create

a promising regulatory path with the FDA.

We are highly confident in the path ahead for the Company and

the potential of our drug pipeline to improve the lives of patients while driving value for stockholders.

We Urge Stockholders to Reject the Attempt by PVG Asset Management

Corporation and

Patrick Adams to Take Control of the Company

On July 24, 2026, Patrick Adams and his firm PVG Asset Management

Corporation (“PVG”) filed a preliminary proxy statement with the SEC (the “PVG Proxy Statement”) seeking to replace

the entire Board of Anavex. We believe the PVG Proxy Statement is significantly deficient, does not comply with applicable SEC rules and

regulations, includes misleading statements and omits material information. Among other things, it provides insufficient information with

respect to PVG, Mr. Adams and the other director nominees, their background and security ownership, agreements with third parties with

respect to the proxy solicitation and other critical information necessary for our stockholders to evaluate the qualifications of the

nominees (or the lack thereof) and conflicts of interest. In addition, the PVG Proxy Statement lacks any discussion of any plan or strategy

for Anavex going forward, which leads us to conclude that PVG and Mr. Adams are seeking to gain effective control of the Company without

paying you a premium for your investment, despite only owning 0.35% of the Company’s outstanding shares of common stock as of July

30, 2026.

We believe that electing Mr. Adams or any of his nominees would

be highly risky and potentially value destructive by creating further disruption at this critical time for the Company.

Anavex’s preliminary proxy statement and, after the filing

thereof, its definitive proxy statement can be accessed for free by visiting EDGAR on the SEC website at www.SEC.gov. Once Anavex files

its definitive proxy materials with the SEC, they will also be mailed to stockholders and include a WHITE proxy card with instructions

on how to vote FOR all six directors comprising the refreshed Anavex Board. Your vote FOR all six directors comprising the

refreshed Anavex Board on the WHITE card will be critical.

We look forward to engaging with investors as we move toward

the 2026 Annual Meeting and are unwavering in our commitment to act in the best interests of the Company and all stockholders.

Sincerely,

Dr. Jiong Ma

Independent Chair

Dr. Peter Donhauser

Independent Director

Dr. Axel Paeger

Independent Director

Dr. Claus van der Velden

Independent Director

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical

company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric

disorders. Further information is available at www.anavex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the

Company’s plans, strategies and expectations regarding the 2026 Annual Meeting, director nominations, the proxy solicitation, the

Company’s go-forward strategy, clinical development programs, business prospects, and potential actions of the Board and the Executive

Committee, are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the

words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,”

“may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many

factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including the risks

and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent

filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not

to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are

qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update

this press release to reflect events or circumstances after the date hereof except as required by law.

Important Additional Information and Where to Find It

The Company intends to file a definitive proxy statement on Schedule 14A,

an accompanying WHITE proxy card, and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s

stockholders for the 2026 Annual Meeting. THE COMPANY’S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE

PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND OTHER DOCUMENTS FILED WITH THE

SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able

to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents that the Company files

with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s

website at www.anavex.com.

Certain Information Regarding Participants

The Company, its directors and certain of its executive officers may be

deemed to be “participants” (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation

of proxies from the Company’s stockholders in connection with the matters to be considered at the 2026 Annual Meeting. Information

regarding the names of the Company’s directors and executive officers and certain other individuals and their direct or indirect

interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Compensation of Directors,”

“Executive Compensation,” and “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (available here), and any

subsequent filings on Forms 3, 4 and 5 filed with the SEC. Additional information regarding the identity of potential participants, and

their direct or indirect interests, by security holdings or otherwise, will be set forth in the Company’s definitive proxy statement

for the 2026 Annual Meeting when it is filed with the SEC. These documents are available free of charge at the SEC’s website at

www.sec.gov.

Investor Relations:

SCR Partners, LLC

Alex Arzeno

Tel: 203-550-3972

Email: alex@scr-ir.com

Tripp Sullivan

Tel: 615-942-7077

Email: tsullivan@scr-ir.com

For Media:

Collected Strategies

Nick Lamplough / Dylan O’Keefe

AVXL-CS@collectedstrategies.com

GRAPHIC

Filename: image_001.jpg · Sequence: 3

Binary file (3103 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 03, 2026

Entity File Number

001-37606

Entity Registrant Name

ANAVEX

LIFE SCIENCES CORP.

Entity Central Index Key

0001314052

Entity Tax Identification Number

98-0608404

Entity Incorporation, State or Country Code

Entity Address, Address Line One

630

5th Avenue

Entity Address, Address Line Two

20th Floor

Entity Address, City or Town

New

York

Entity Address, State or Province

Entity Address, Postal Zip Code

10111

City Area Code

844

Local Phone Number

689-3939

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.001 per share

Trading Symbol

AVXL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration